TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a first episode of idiopathic proximal deep vein thrombosis who have been treated during 6 months (Plus or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.~Exclusion Criteria:~* Age \> 18~* warfarin hypersensibility~* unwilling or unable to give writting informed consent~* distal deep vein thrombosis or pulmonary embolism~* Proximal deep vein thrombosis which was provoked by a reversible major risk factor~* major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)~* previous documented episode of proximale deep vein thrombosis or pulmonary embolism~* other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)~* patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation~* pregnancy~* women without contraception~* planned major surgery in the next 18 months~* ongoing cancer or cured cancer in less than 2 years~* serious bleeding risk (e.g.: gastric ulcer)~* platelet count less than 100 Giga/l~* Life expectancy less than 18 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 18 months of active warfarin therapy
- 2 (Type: PLACEBO_COMPARATOR): 18 months of placebo of warfarin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male or female subjects.~* Aged 18 to 45 years old.~* Low-density lipoprotein cholesterol \>100 mg/dL (2.59 mmol/L).~Exclusion criteria:~* Subjects with any history or presence of clinically relevant illness.~* Serum triglycerides \>200 mg/dL (2.26 mmol/L) measured after at least 10 hour fasting.~* Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening, including but not limited to statins, ezetimibe, fibrates, niacin, or bile acid resins. Use of probucol within 8 weeks prior to screening.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Alirocumab (Type: EXPERIMENTAL): Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injection of a single dose of matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aripiprazole in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-65 years old who have experienced single or recurrent, non-psychotic episodes of Major Depressive Disorder, with the current episode of minimally 8 weeks in duration.~* Treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): None
- A2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Irritable Bowel Syndrome (ROME III criteria)~* age 18-65 years~Exclusion Criteria:~* medication: antidepressants or H1-receptor antagonists~* pregnancy, breast feeding~* co-morbidity: severe kidney- and/or liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo capsule (Type: PLACEBO_COMPARATOR): None
- ebastine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Active and severe ankylosing spondylitis~* Ankylosing spondylitis refractory to standard anti-rheumatic treatment~* Between 18 and 70 years of age~Exclusion criteria~* Prior exposure to any TNF-inhibitor, including etanercept~* DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation~* Dose of NSAIDs changed within two weeks of study drug initiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years and older~2. Invasive mechanical ventilation ≥ 48 hours~3. Satisfy the US Centers for Disease Control and Prevention National Healthcare Safety Network VAP diagnostic criteria~   * At least one of the following:~     1. temperature \> 38 °C~    2. white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3~    3. altered mental status with no other causes in \>70 year-olds; AND~  * Two or more chest imaging tests demonstrating at least one of the following:~     1. new and progressive OR progressive and persistent infiltrate~    2. new and persistent OR progressive and persistent consolidation~    3. new and persistent OR progressive and persistent cavitation, AND~  * At least two of the following:~     1. new onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased in suctioning requirements~    2. new onset or worsening tachypnea or dyspnea~    3. rales or bronchial breath sounds~    4. worsening gas exchange defined by oxygen desaturations (e.g., PaO2/FiO2 \<240), increased oxygen requirements or increased ventilation demand~Exclusion Criteria:~1. Poor likelihood of survival as defined by a Sepsis-related Organ Failure Assessment score (SOFA score) of \>11 points~2. Immunocompromised patients (HIV with CD4 \<200 cells/mm3, corticosteroids\> 0.5 mg/kg per day for \> 30 days, received chemotherapy in the past 3 months, solid organ or hematopoietic cell transplant)~3. Patients receiving antibiotic therapy for any other defined extra-pulmonary infections that warrant a duration of antibiotics longer than 7 days, or complications of pneumonia such as lung abscess or empyema, that warrant a duration of antibiotics longer than 7 days (excluding anti-tuberculosis treatment, antifungal medications, antibiotics meant for chronic suppression of chronic infections or chronic obstructive lung disease)~4. Patients who have been treated for VAP for more than 7 days from screening~5. Vulnerable population including prisoners and refugees

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short antibiotic treatment duration for VAP (7 days or less) (Type: ACTIVE_COMPARATOR): None
- Long antibiotic treatment duration for VAP ( 8 days or more) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior Myocardial Infarction~* An implantable defibrillator~* One of the following VT events (within the past 3 months):~  * greater than or equal to 3 episodes of symptomatic VT treated with ATP~ * greater than or equal to 1 appropriate ICD shock~ * greater than or equal to 3 VT episodes within 24 hours~ * sustained VT below detection rate of the ICD documented by ECG~* Failed first-line antiarrhythmic drug therapy as defined by one of:~  * Appropriate ICD therapy or sustained VT occurred while patient was taking amiodarone (stable dose \>/= 2 weeks)~ * Appropriate ICD therapy or sustained VT occurred on another antiarrhythmic drug (stable dose \>/= 2 weeks)~Exclusion Criteria:~* Active ischemia (acute thrombus, dynamic ST elevation on ECG) or another reversible cause of VT (eg. electrolyte abnormalities, drug induced arrhythmia)~* Are known to be ineligible to take amiodarone (eg. active hepatitis, current hyperthyroidism, pulmonary fibrosis, known allergy)~* Are ineligible for ablation (left ventricular thrombus, implanted mechanical aortic and mitral valves)~* Renal Failure (creatinine clearance \< 15 ml/min)~* Current NYHA functional class IV heart failure or CCS Functional Class IV angina~* Recent ST elevation myocardial infarction (\< 1 month)~* Recent coronary bypass surgery (\< 3 mon) or recent PCI (\< 1 mon)~* Pregnant~* prior ablation for ventricular tachycardia~* A systemic illness likely to limit survival to \< 1 year~* Unable or unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ventricular Tachycardia Ablation (Type: ACTIVE_COMPARATOR): Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
- Escalated Antiarrhythmic Drug Therapy (Type: ACTIVE_COMPARATOR): Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bronchoscopy and Bispectral Index (BIS) - Guided Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for bronchoscopy~* ASA I to III~* age between 18 and 79 years~* capacity of discernment~Exclusion Criteria:~* visual and psychological problems that might interfere with psychometric testing~* chronic obstructive pulmonary disease with FEV1 \< 50% predicted~* need for an airway intubation or laryngeal mask insertion~* fever or other signs of systemic infection~* hemodynamic instability defined as a resting heart rate (HR) \< 60 or ≥ 120 and/or a systolic blood pressure (BP) \< 100 or \> 180 mmHg~* significant liver disease and documented soy allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): i.v. midazolam titration until adequate depth of sedation
- Propofol (Type: ACTIVE_COMPARATOR): i.v. propofol titration until adequate depth of sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* confirmed and active CLL requiring treatment~* at least one previous treatment for CLL and having achieved a complete or partial remission/response but after a period of 6 or more months, shows evidence of disease progression~* fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours~* age 18yrs or older~* signed written informed consent~Key Exclusion Criteria:~* diagnosis of refractory CLL (failure to achieve a complete or partial remission/response or disease progression within 6 months of last anti-CLL treatment~* abnormal/inadequate blood values, liver and kidney function~* certain heart problems, serious significant diseases, AIHA, other current cancers or within the last 5 years~* active or chronic infections~* use of drugs to suppress allergic or inflammatory responses (glucocorticoids)~* CLL transformation~* CLL central nervous system involvement~* current participation in other clinical study~* inability to comply with the protocol activities~* lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab, Fludarabine, Cyclophosphamide (Type: EXPERIMENTAL): Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
- Fludarabine, Cyclophosphamide (Type: ACTIVE_COMPARATOR): Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study for Solid Metastatic Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed breast cancer or other cancer which is persistent and metastatic or recurrent and metastatic.~* Patients with a history of treatment for other prior malignancy will be eligible, provided they remain disease-free \> 2 years after initial treatment, or were treated for non-melanoma skin cancer, or in situ cervical cancer.~* Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of larger in their largest diameter.~* Age \>18 years.~* ECOG performance status \<2 (Karnofsky \>50%).~* Life expectancy \> 3 months.~Exclusion Criteria:~* Patients who have had immunotherapy within 4 weeks prior to entering the study.~* Patients who have had prior allergic reaction to GM-CSF~* Patients on steroid therapy or other immunosuppressive therapy.~* Patients undergoing therapy with other investigational agents.~* Patients with known brain metastases can be included in this clinical trial but brain lesions are not eligible as target or non target lesion.~* Uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the past 6 months, unstable angina pectoris, or unstable cardiac arrhythmia requiring assessment for clinical intervention.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Radiation therapy (Type: EXPERIMENTAL): Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipid Lowering in Patients With Statin Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Baseline cholesterol - LDL more than 160 with one risk factor or LDL more than 130 with 2 or more risk factors for developing coronary artery disease (Smoker, age \>40, male, Family history, diabetes, obesity) utilizing ATP III guidelines~2. Have had a statin prescribed by a doctor for high cholesterol, and have stopped medication because of side effects~3. Ability to exercise without physical restrictions~4. Ability to attend 12 week consecutive Change of Heart sessions~5. Not taking any cholesterol lowering medication for at least 1 month prior to initiation of trial. Not taking red yeast rice for at least 1 month prior.~Exclusion Criteria:~1. Any active cardiac problem including chest pain, angina, shortness of breath with minimal activity, or unstable angina/acute coronary syndrome within one year~2. Known intolerance to one of the study drugs~3. Physical limitation preventing aerobic exercise program, such as severe arthritis, peripheral vascular disease, congestive heart failure, or symptom limiting pulmonary disease~4. Uncontrolled hypertension (defined as SBP\>180 mmHg or DBP \> 100mmHg.~5. Heart attack, bypass surgery, or angioplasty/stent within 1 year of study~6. Triglyceride level more than 400 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): placebo control
- 2 (Type: ACTIVE_COMPARATOR): red yeast rice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults \>=18 years of age;~* currently on antiretroviral (ARV) therapy;~* previously treated with 2 or 3 different antiretroviral classes;~* HIV-1 Ribonucleic acid (RNA) \>=1,000 copies/mL;~* Cluster differentiation antigen four (CD4) lymphocyte count \>=200 cells/mm\^3;~* females of childbearing potential must be willing to use a reliable form of effective barrier contraception for the duration of the study and for 30 days after the last dose of study drug.~Exclusion Criteria:~* history of prior use of enfuvirtide or T-1249;~* women who are pregnant, breastfeeding or planning to become pregnant during the study;~* active, untreated opportunistic infection;~* patients on treatment interruption, or patients interrupting ARV therapy within 4 weeks of screening or during the screening period for reasons either than toxicity management.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ENF + HAART (Type: EXPERIMENTAL): Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
- HAART (Type: ACTIVE_COMPARATOR): Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: ECT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First or second pregnancy~* Greater than 16 weeks gestation~* Less than 28 weeks gestation~* Consent for HIV testing~Exclusion Criteria:~* Less than 15 years old

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete